
March 6 (Reuters) - Lisata Therapeutics Inc LSTA.O:
LISATA THERAPEUTICS ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY KUVA LABS, INC.
LISATA THERAPEUTICS INC - KUVA TO BUY LISATA FOR $5.00 PER SHARE IN CASH PLUS ONE CVR PER SHARE
LISATA THERAPEUTICS INC - CVR ENTITLES ADDITIONAL $1.00 PER SHARE IF NDA FOR CERTEPETIDE IS FILED OR ACCEPTED
LISATA THERAPEUTICS INC - BOARD UNANIMOUSLY APPROVES DEAL AND RECOMMENDS STOCKHOLDERS TENDER SHARES
LISATA THERAPEUTICS INC - TO BE DELISTED FROM NASDAQ AND DEREGISTER AS REPORTING COMPANY AFTER DEAL CLOSE